Clinical Trial Update: An Open-Label, Single- & Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects (0431-108)(COMPLETED) [Phase 1]

View source ↗

Summary

This completed Phase 1 open-label study assessed the pharmacokinetics of sitagliptin 100 mg after single and multiple doses in healthy Chinese adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Januvia (sitagliptin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Diabetes Mellitus Non-insulin-dependent | Phase 1 | Status: COMPLETED